SCHEMBL6177777

SCHEMBL6177777

CC(C)COCOC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13316781 0.95 MAPK1 (0.41) MAPK1
SCHEMBL13316783 0.81 MAPK1 (0.38) MAPK1
SCHEMBL137282 0.77
SCHEMBL7522404 0.77 MAPK1 (0.42) MAPK1
SCHEMBL15280690 0.77 MAPK1 (0.37) MAPK1
SCHEMBL15280694 0.77 MAPK1 (0.37) MAPK1
SCHEMBL723652 0.76 ALDH1A1 (0.38)
SCHEMBL212537 0.76 MAPK1 (0.36) MAPK1
SCHEMBL19426800 0.75 MAPK1 (0.41) MAPK1
SCHEMBL17927986 0.75 MAPK1 (0.41) MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3543243-B1 PROCESS FOR THE PREPARATION OF CUCURBITURIL DERIVATIVES AQDOT LTD (GB) 2022-02-02 EP claimed
US-10626119-B2 Process for the preparation of cucurbituril and/or one or more derivatives thereof AQDOT LIMITED (GB) 2020-04-21 US claimed
EP-3543243-A1 PROCESS FOR THE PREPARATION OF CUCURBITURIL DERIVATIVES Aqdot Limited (GB) 2019-09-25 EP claimed
US-20190241579-A1 PROCESS FOR THE PREPARATION OF CUCURBITURIL AND/OR ONE OR MORE DERIVATIVES THEREOF AQDOT LIMITED (GB) 2019-08-08 US claimed
US-20180244681-A1 PROCESS AQDOT LIMITED (GB) 2018-08-30 US claimed
WO-2018115822-A1 PROCESS FOR THE PREPARATION OF CUCURBITURIL DERIVATIVES AQDOT LIMITED (GB) 2018-06-28 WO claimed
EP-3543243-B1 PROCESS FOR THE PREPARATION OF CUCURBITURIL DERIVATIVES AQDOT LTD (GB) 2022-02-02 EP disclosed
US-10626119-B2 Process for the preparation of cucurbituril and/or one or more derivatives thereof AQDOT LIMITED (GB) 2020-04-21 US disclosed
EP-3543243-A1 PROCESS FOR THE PREPARATION OF CUCURBITURIL DERIVATIVES Aqdot Limited (GB) 2019-09-25 EP disclosed
US-20190241579-A1 PROCESS FOR THE PREPARATION OF CUCURBITURIL AND/OR ONE OR MORE DERIVATIVES THEREOF AQDOT LIMITED (GB) 2019-08-08 US disclosed
EP-3359543-B1 CUCURBITURIL DERIVATIVES AQDOT LTD (GB) 2019-06-26 EP disclosed
US-10308657-B2 Composition comprising cucurbituril and/or one or more derivatives thereof AQDOT LIMITED (GB) 2019-06-04 US disclosed
US-20180244681-A1 PROCESS AQDOT LIMITED (GB) 2018-08-30 US disclosed
US-7378518-B2 Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2008-05-27 US disclosed
US-20070155676-A1 Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2007-07-05 US disclosed
US-7208486-B2 Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2007-04-24 US disclosed
EP-0945445-B9 1,5-BENZODIAZEPINE DERIVATIVES ZERIA PHARM CO LTD (JP) 2005-12-28 EP disclosed
EP-0945445-B1 1,5-BENZODIAZEPINE DERIVATIVES ZERIA PHARM CO LTD (JP) 2003-09-03 EP disclosed
US-6239131-B1 WHICH HAVE GASTRIN AND/OR CCK-B (CHOLECYSTOKININ-B) RECEPTOR ANTAGONISM, USEFUL AS REMEDIES FOR GASTRIC ULCER AND GASTROINTESTINAL MOVEMENT DISORDER. ZERIA PHARMACEUTICAL CO., LTD. (JP) 2001-05-29 US disclosed
EP-0945445-A1 1,5-BENZODIAZEPINE DERIVATIVES ZERIA PHARMACEUTICAL CO., LTD. (JP) 1999-09-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180244681-A1 PROCESS UCHL3, UCHL5, CBR3 MAPK1 3545/4885
US-10626119-B2 Process for the preparation of cucurbituril and/or one or more derivatives thereof UCHL3, UCHL1, UCHL5 MAPK1 2982/4885
US-10308657-B2 Composition comprising cucurbituril and/or one or more derivatives thereof UCHL3, CBR3, UCHL5 MAPK1 4185/4885
US-20190241579-A1 PROCESS FOR THE PREPARATION OF CUCURBITURIL AND/OR ONE OR MORE DERIVATIVES THEREOF UCHL3, UCHL1, UCHL5 MAPK1 2982/4885
US-20070155676-A1 Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof APOB, NPC1L1, CYP46A1 MAPK1 3541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.